西罗莫司洗脱支架治疗糖尿病冠脉狭窄病变的临床研究

Sirolimus Eluting Stent in The Treatment of Diabetes Mellitus Coronary Artery Stenosis Clinical Study

目的评价西罗莫司洗脱支架治疗糖尿病患者冠状动脉狭窄病变的安全性和临床疗效。方法 73例糖尿病合并冠心病患者入选研究,观察西罗莫司洗脱支架或紫杉醇涂层支架植入后12个月的主要心血管不良事件(MACE)及再狭窄率。结果接受两种支架植入的患者基本临床特征相似,均完成了12个月随访。西罗莫司洗脱支架组MACE事件发生率和再狭窄率分别为9.52%和4.76%,紫杉醇涂层支架组相应为9.67%和6.45%,两组比较差异无统计学意义(P>0.05)。结论西罗莫司洗脱支架治疗糖尿病冠状动脉狭窄病变同紫杉醇涂层支架一样安全有效,在降低MACE和再狭窄方面疗效满意。

Objective To evaluate efficacy and the short-term clinical outcomes of sirolimus eluting stent（FirebirdTM） in treatment of coronary disease patients with type 2 diabetes.Methods 73 patients were treated with sirolimus eluting stent（n=42） or paclitaxel eluting stent（TaxusTM,n=31）.The outcomes during 12 month follow-up were analyzed.Results Major adverse cardiac event（MACE） and restenosisrate were respectively 9.52% and 4.76% in group of FirebirdTM,9.67% and 6.45% in group of TaxusTM（P0.05）.Conclusion The efficacy of sirolimus eluting stent was similar to paclitaxel eluting stent in coronary disease patients with type 2 diabetes.